Stock info Epigenomics | Filter  Basic-Info

Epigenomics

The global health care companies gained around 102 percent worldwide over the last 10 years. Measured since 2011 the sector is 64 percent higher and over the past 12 months (December 2015-2016) there is a plus of 102 percent.

The past year was a good investment year for Epigenomics investors

Over the last 12 months, that were profitable period for the investors in Epigenomics, the stock gained around 94 percent. Over the period from December 2011 till December 2016 the stock rose on average 169 percent. Epigenomics's revenues between 2011 and 2015 were very volatile through the time and moved between 1,04 million euros and 2,08 million euros. Epigenomics's net incomes between 2011 and 2015 were very volatile through the time and moved between -15,58 million euros and -8,99 million euros.

Over the past 5 years the German company paid out dividends.

Epigenomics financed with relatively low debt

At the end of 2015 the health care company's balance sheet was worth 12,6 million euros. Of the total balance sheet 5,5 million euros (43,65 percent) was financed by debt. As per the end of 2015 Epigenomics's price/earnings-ratio equaled -10. So investors paid for 1 stock -10 times the earnings per share of 2015. Many analysts say that based on her price/earnings-ratio and dividend yield the German stock can be seen as a value stock.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the health care company equaled around 38,51 million euros. At the end of 2015 the German company had around 17,12 million stocks listed on the exchanges.

On this page you can find all Epigenomics's financial reports. More information about Epigenomics can be found it's website. .